logo-loader
viewVitality Biopharma, Inc.

Vitality Biopharma CEO says cannabinoids have potential for neurological/inflammatory conditions

Vitality Biopharma (OTCQB:VBIO) CEO Robert Brooke tells Proactive Investors about the company's development of cannabinoid prodrug pharmaceuticals and how cannabinoids can be used for the treatment of serious neurological and inflammatory disorders.

Brooke says the cannabinoid prodrugs (known as cannabosides) can, upon ingestion, enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. This could be used by people with conditions such as Crohn's, IBS and colitis.

Brooke says cannabinoids also have the potential to be used as an alternative to opiate abuse.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Trigg Mining's Keren Paterson reports on 'fantastic high-grade results' from...

Trigg Mining Ltd (ASX:TMG) managing director Keren Paterson updates Proactive's Andrew Scott on the results from a recent drill programme at its Lake Throssell SOP Project in WA. She says they put 26 holes across the project and the assay results have them very excited. ''They've all pretty much...

18 hours, 32 minutes ago

2 min read